The drug therapy for adults patients with Kashin-Beck disease

The drugs effect on adults' Kashin-Beck disease

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-09000395

Enrollment

Unknown

Registered

2009-06-01

Start date

2007-11-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Median and serious disfunction of adults' Kashin-Beck disease

Interventions

A group:Celebrex

B group:Meloxicam

C group:Glucosamine

D group:Diacerein

E group:Naproxen

F group:Ibuprofen

H group:Ibuprofen

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Median and serious disfunction of adults' Kashin-Beck disease

Exclusion criteria

Exclusion criteria: ,

Design outcomes

Primary

Measure	Time frame
Western Ontario and McMaster Universities Osteoart;visual analogue pain scale;	—

Contacts

Public ContactPei Fuxing

peifuxing@vip.163.com+86 028 81812380

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026